Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALIANT: Verekitug in Severe Asthma
NCT06196879Phase 2Completed
- Sponsor
- Upstream Bio
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of vereckitug in severe asthma (4 arms), sponsored by Upstream Bio. Primary endpoint: Annual Asthma Exacerbation Rate at 60 weeks. Started Feb 2024; status: completed.
02
Drugs
vereckitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT06196879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196879.